Can Johnson & Johnson’s oral Icotyde compete with biologics in psoriatic arthritis?
Icotyde achieved 58% ACR20 in Phase 3 psoriatic arthritis, but the 400 mg dose added no benefit. Can Johnson & Johnson challenge biologics?
Pharma & Biotech
Pharma & Biotech
Johnson & Johnson reports long-term ICOTYDE efficacy and safety in plaque psoriasis
Johnson & Johnson reports two-year ICOTYDE psoriasis results, with over 72% achieving PASI 90. See what the data mean for treatment.
Pharma & Biotech
FDA approves Takeda’s MIMRYLO as first hepcidin mimetic for polycythemia vera
The U.S. Food and Drug Administration has approved once-weekly MIMRYLO, or rusfertide, for erythrocytosis in adults with polycythemia vera, introducing the first therapy designed to mimic the iron-regulating hormone hepcidin.
Pharma & Biotech
What will Silence Therapeutics’ SANRECO Phase 2 results reveal about divesiran in polycythemia vera?
Silence Therapeutics will reveal Phase 2 SANRECO divesiran results in polycythemia vera, testing hematocrit control and phlebotomy reduction.